Latest News

Depression in PD often untreated despite improved detection

 

A retrospective analysis of the U.S. National Parkinson’s Foundation (NPF) database has found that clinical recognition of depression in Parkinson’s disease has improved but almost one-half of patients remain untreated (Bega et al. J Parkinsons Dis 2014; epublished July 17, 2014; free full text at http://iospress.metapress.com/content/92617284j0410402/fulltext.pdf). The study was part of the NPF’s Quality Improvement Initiative. Read More

TOPICS:

New data on first-line oral therapies in MS

 


ECTRIMS highlights

Long-term data
Safety studies
Comment: Dr. Mark S. Freedman, Director, Multiple Sclerosis Research Unit, The Ottawa Hospital, Ottawa, Canada

The 31st congress of the European Committee for Treatment and Research in MS (ECTRIMS) featured new research on current therapies for multiple sclerosis. In Canada, two oral therapies – teriflunomide and dimethyl fumarate (DMF) – are routinely used as first-line agents. The following summarizes key data for these two therapies presented at ECTRIMS. Read More